IN PHASE 3 TRIALS

Retatrutide

The "triple agonist" weight-loss drug producing the largest weight-loss numbers ever recorded in a clinical trial. Eli Lilly's follow-up to tirzepatide. Not yet approved. Phase 3 results have been positive, but the FDA hasn't ruled.

The 30-second read

Retatrutide hits three hormone receptors at once. GLP-1, GIP, and glucagon, instead of one or two like the drugs already on the market. In Phase 2, the highest dose produced about 24% weight loss over 48 weeks. The Phase 3 TRIUMPH program is reading out across 2025 and 2026 with results in the high-20%s and even into the low-30%s in some arms, the largest figures any weight-loss drug has produced in a controlled trial. It's a weekly injection, prescription-only when approved, and Eli Lilly's submission to the FDA is expected to land in 2026 with potential approval in 2027–28. Side-effect profile is similar to other GLP-1 drugs: GI issues during titration. Promising, but not approved yet.

Why this peptide is on people's radar

Tirzepatide showed that adding a second hormone receptor (GIP) to GLP-1 produced bigger weight loss than GLP-1 alone. Retatrutide asked the obvious next question: what happens with three receptors at once? Eli Lilly added glucagon-receptor activity to the mix, which sounds counterintuitive, glucagon raises blood sugar, but in this combination it appears to help by burning more energy through the liver and increasing metabolic rate.

The Phase 2 data made the case. In a 48-week study, the highest dose of retatrutide produced about 24.2% mean weight loss in adults with obesity. As Phase 3 results have rolled in across the TRIUMPH program in 2025 and 2026, the numbers have continued to surprise, figures into the high-20%s and beyond, with some patient subgroups in the low-30%s. For context: Wegovy is approved with about 15%, Zepbound with about 21%. Retatrutide's data, if it holds across the program, would be the largest weight-loss effect any approved or near-approved medication has produced.

Mainstream coverage has been heavy: New York Times, TIME, STAT, CNBC, Reuters, NPR. Eli Lilly's submission to the FDA is expected in 2026 based on company guidance, with potential approval and launch in 2027–28. People are watching closely.

What people are usually trying to do with it

Most people reading about retatrutide are watching it for one of these reasons:

  • Hoping for a more effective option than what's currently on the market
  • Wanting to lose weight beyond what tirzepatide or semaglutide produced for them
  • Following the cardiovascular and metabolic outcomes data as it emerges
  • Watching for type 2 diabetes outcomes from a triple-mechanism drug
  • Tracking where this fits into the broader treatment landscape if it's approved

What the science actually shows

Retatrutide has the most striking weight-loss numbers of any drug in this class so far. Plain-English summary of what published trial data has reported:

Phase 2 weight loss

Published in NEJM, the 48-week Phase 2 trial reported about 24.2% mean weight loss at the highest dose (12 mg weekly) in adults with obesity. About a quarter of participants lost more than 30% of their baseline body weight.1

Phase 3 (TRIUMPH program)

Phase 3 results have been reading out across 2025–2026. Topline figures across arms have ranged from about 22% to over 28% mean weight loss, with some patient subgroups in the low-30%s. Full publications are tracked in the TRIUMPH portfolio.2

Type 2 diabetes outcomes

Phase 2 data in adults with T2D reported larger A1C reductions than other GLP-1-class drugs in the comparator arms, alongside weight loss in the 16–17% range at higher doses.3

Cardiometabolic markers

Improvements in blood pressure, triglycerides, liver-fat measurements (a meaningful piece of the metabolic-syndrome picture), and waist circumference. The cardiovascular-outcomes program is later-stage.4

What's not yet known

Long-term safety beyond trial duration. What happens when people stop. Real-world tolerability outside trial conditions. Cost and access, none of that is established because the drug isn't approved yet.

The honest read

What's solid:

The Phase 2 data and the Phase 3 readouts that have published so far are remarkable, the largest controlled-trial weight-loss numbers any medication has produced. The mechanism is coherent. Eli Lilly's regulatory track record and manufacturing capacity are real. The submission and review path is well-defined.

What's still unproven:

FDA approval has not happened yet. Long-term safety data, cardiovascular outcomes, and real-world tolerability outside trial conditions are still being collected. What the maintenance picture looks like (does it have a stronger or weaker regain pattern than tirzepatide?) is not yet established. Cost and access are unknown.

What's hyped beyond the evidence:

Treating it as available now. It isn't, it's an investigational drug, and the only legitimate way to access it as of 2026 is through a clinical trial. "Compounded retatrutide" being marketed online is not the FDA-approved drug (it doesn't exist yet) and isn't operating under the manufacturing oversight that comes with approval. Also: assuming the Phase 3 numbers will translate exactly into real-world results, they almost never do.

Things to know if you're looking into it

  • Investigational status: retatrutide is in Phase 3 trials. It is not FDA-approved and is not commercially available. The legitimate way to access it as of 2026 is through enrollment in a clinical trial (ClinicalTrials.gov is the place to look).
  • Compounded retatrutide is not the drug: any product marketed as "compounded retatrutide" online is not the FDA-approved drug (which doesn't yet exist). It isn't operating under the manufacturing oversight that comes with approval. The FDA has been clear about this.
  • Triple mechanism: retatrutide engages three receptors. GLP-1 and GIP (the same as tirzepatide) plus glucagon. The glucagon component is what's new and what appears to add the additional metabolic effect.
  • Common side effects in trials: nausea, diarrhea, vomiting, decreased appetite, similar to the rest of the GLP-1 class. Slow titration is the standard mitigation. Some additional considerations around the glucagon-receptor effects on heart rate and blood pressure.
  • Expected approval timing: Eli Lilly has guided to a 2026 FDA submission with potential approval in 2027–28 if the program goes well. Real life often shifts these timelines.
  • Specific dosing protocols, mechanism, half-life, and full TRIUMPH trial detail: all in the "Want to go deeper?" section below.

Reconstitution & dose calculator

Investigational compound. Retatrutide is in Phase 3 trials and is not FDA-approved. The dose framing below summarizes what published trials have used. This calculator is an educational reference, not dosing guidance.
Suggested start
0.5 mg/week
Trial titration starts at 0.5 mg weekly
Common range
4–8 mg/week
Where most weight-loss data lives
Max dose
12 mg/week
Highest dose used in TRIUMPH trials
Cycle
Continuous
Weekly titration over months
mL
Defaults to a 5 mg/mL dilution (10 mg/mL on the 30 mg vial) — lower concentration gives more precision on the syringe at low doses. Adjust to taste.
mg
Once-weekly subcutaneous dosing in trials.
Concentration
5.0 mg/mL
Per dose
0.10 mL
10 units on insulin syringe
Doses per vial
~24
~24 weeks of weekly dosing

When to stay put vs. escalate

Stay put when GI side effects (nausea, vomiting, diarrhea) are present at all, when you've been at the current dose less than four weeks, or when the dose is producing the response you're after. Tolerability and steady results are the signal to hold, not to push.

Consider escalating only after at least four weeks at the current dose, when GI effects have settled to baseline, when weight-loss progress has clearly plateaued, and when you have headroom toward your goal. Trial protocols use four-week steps for a reason — the GI tolerability profile depends almost entirely on slow titration.

Don't stack steps. Skipping titration rungs in pursuit of faster results is the most reliable way to produce intolerable side effects and drop out of treatment entirely.

For educational and research purposes only. This is not medical advice. Retatrutide is investigational and is only legitimately accessible through enrolled clinical trials. Consult a licensed healthcare provider before any health decision.

What people often ask

Is retatrutide approved?

No. As of May 2026, retatrutide is in Phase 3 clinical trials. Eli Lilly is expected to submit to the FDA in 2026, with potential approval in 2027–28 if the trial program reads out well.

How does it differ from tirzepatide?

Tirzepatide hits two receptors (GLP-1 and GIP). Retatrutide adds a third (glucagon). The glucagon-receptor activity appears to add metabolic-rate and liver-fat effects on top of the appetite suppression and insulin signaling that the GLP-1 / GIP combo already produces.

How much weight do people lose?

In the Phase 2 trial, the highest dose produced about 24.2% mean weight loss over 48 weeks. Phase 3 readouts that have published have been in similar territory or higher, with some subgroups losing into the 30%s. Individual results vary widely.

Why is glucagon part of the picture? Doesn't it raise blood sugar?

It does, in the short term. But chronic glucagon-receptor activation also increases energy expenditure (more calories burned), reduces liver fat, and influences fat metabolism. The combined effect of GLP-1 + GIP + glucagon appears to net out positive in trials. The trade-offs at higher doses are still being characterized.

What about the side effects?

Most reported side effects are GI: nausea, diarrhea, vomiting, common to the entire GLP-1 class. Slow titration helps. The glucagon-receptor effects can also influence heart rate, which is being tracked in the trials.

How can I get retatrutide?

Through a clinical trial. ClinicalTrials.gov is the official registry, searchable by your geography. Anything sold as "retatrutide" online by non-trial sources isn't the FDA-approved product (because that doesn't exist yet), isn't subject to FDA manufacturing oversight, and shouldn't be confused with the investigational drug.

When will it be approved?

If everything goes well: FDA submission expected in 2026, decision in 2027–28. Trial readouts and regulatory feedback can shift those timelines either way.

FDA and regulatory status

Status as of May 5, 2026: Investigational. Not FDA-approved for any indication. Currently in Phase 3 trials (TRIUMPH program for chronic weight management; additional programs for type 2 diabetes and cardiometabolic outcomes). Eli Lilly has publicly guided to a 2026 FDA submission for the chronic-weight-management indication, with potential approval in 2027–28 if Phase 3 reads out well. Status updates land here when they happen.

Notable commentary

Retatrutide's trial readouts have driven heavy mainstream coverage. Editorial reporting, not clinical evidence on its own.

TRIUMPH program coverage

Each new readout has produced a wave of coverage that helps translate clinical-trial numbers into something a general reader can interpret.

Editorial coverage of investigational-drug clinical trials. For educational purposes only.

Want to go deeper? Mechanism, dosing schedule, the TRIUMPH program detail, side-effect profile, and references. Click to expand.

Background and development

Retatrutide is a synthetic peptide developed by Eli Lilly. It is the first investigational drug to engage three incretin and glucose-regulating receptors simultaneously: GLP-1 (the same as semaglutide), GIP (the same target tirzepatide added on top of GLP-1), and the glucagon receptor (the new addition). The triple-mechanism design is intended to combine appetite suppression and improved insulin signaling with the energy-expenditure and liver-fat effects of glucagon-receptor activation.

Mechanism of action

GLP-1 receptor activation

Promotes glucose-dependent insulin release, slows gastric emptying, and reduces appetite via central nervous system effects.

GIP receptor activation

Adds incretin effect on insulin release and contributes to weight-loss effects, additive to GLP-1 in tirzepatide and beyond.

Glucagon receptor activation

The novel piece. Increases energy expenditure (more calories burned at rest), reduces hepatic fat content, and influences fat metabolism. In acute settings glucagon raises blood glucose, but the combined GLP-1 + GIP signal in retatrutide appears to net out a glucose-lowering and weight-reducing effect across trial data.

Half-life and dosing

Plasma half-life supports once-weekly subcutaneous administration. Doses studied in trials range from 1 mg to 12 mg weekly, with titration over weeks.

Investigational dosing schedule

Investigational only. Retatrutide is not FDA-approved and is only available through clinical trials. The dosing description below summarizes what the published trials have used.

Phase 2 trials titrated patients from 0.5 mg weekly up through 12 mg over several months, with most weight-loss data coming from the 8 mg and 12 mg arms. Phase 3 protocols use similar approaches with the highest fixed dose around 12 mg.

The TRIUMPH program

The Phase 3 TRIUMPH program comprises multiple trials assessing retatrutide for chronic weight management, type 2 diabetes, and cardiometabolic outcomes.

  • TRIUMPH-1, -2, -3: chronic weight management trials, in adults with obesity, with and without comorbidities. Topline readouts have ranged from ~22% to ~28%+ mean weight loss across arms.
  • TRIUMPH-4: the chronic-weight-management trial whose results most heavily drove press coverage. Mean weight loss in some patient subgroups in the low-30%s.
  • TRIUMPH-Diabetes: evaluating retatrutide for type 2 diabetes management.
  • TRIUMPH-Outcomes: cardiovascular-outcomes trial, longer-duration.

Side effects and safety profile

The most common adverse events in trials have been gastrointestinal, nausea, diarrhea, vomiting, constipation, decreased appetite, comparable to the rest of the GLP-1 class, with rates and severity dose-dependent.

The glucagon-receptor component introduces additional considerations: heart rate (modest increases observed in trials), blood pressure, and potential effects on liver enzymes. These are being tracked in the Phase 3 program.

Discontinuation rates due to adverse events have been in the single-digit percentage range in trials, similar to or slightly higher than tirzepatide depending on dose.

The FDA boxed-warning class effects (thyroid C-cell tumors observed in rodent models for the GLP-1 class) are expected to apply to retatrutide if approved. Any prescribing program will screen for personal/family history of medullary thyroid carcinoma and MEN2.

References

  1. Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). "Triple-hormone-receptor agonist retatrutide for obesity, a Phase 2 trial." N Engl J Med, 389(6), 514–526. PubMed
  2. Eli Lilly. "TRIUMPH Phase 3 program, clinical trial readouts." Press releases and SEC filings, 2025–2026. Lilly Investor Relations
  3. Rosenstock J, Frias J, Jastreboff AM, et al. (2023). "Retatrutide in adults with type 2 diabetes, a Phase 2 trial." The Lancet, 402(10401), 529–544. PubMed
  4. Sanyal AJ, Jastreboff AM, Coskun T, et al. (2024). "Effect of retatrutide on liver fat in adults with obesity and metabolic dysfunction-associated steatotic liver disease." Nature Medicine, 30, 2037–2048. PubMed
  5. ClinicalTrials.gov. TRIUMPH program registry. ClinicalTrials.gov
For educational and research purposes only. This is not medical advice. Retatrutide is an investigational drug, not FDA-approved as of May 2026. Legitimate access is through clinical trials (ClinicalTrials.gov). Consult a licensed healthcare provider before any clinical decision. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does.